Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$26.12 - $34.07 $60,076 - $78,361
2,300 Added 1.93%
121,200 $4.13 Million
Q1 2024

May 07, 2024

BUY
$26.64 - $40.31 $2.82 Million - $4.27 Million
106,000 Added 821.71%
118,900 $4.19 Million
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $414,960 - $644,800
-20,800 Reduced 61.72%
12,900 $372,000
Q3 2023

Nov 14, 2023

SELL
$21.33 - $59.42 $317,817 - $885,358
-14,900 Reduced 30.66%
33,700 $772,000
Q2 2023

Aug 11, 2023

SELL
$34.33 - $62.11 $556,146 - $1.01 Million
-16,200 Reduced 25.0%
48,600 $2.79 Million
Q1 2023

May 16, 2023

BUY
$26.01 - $48.69 $1.69 Million - $3.16 Million
64,800 New
64,800 $2.44 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.